TABLE 2

In vitro susceptibilities of 61 Candida auris isolates to five antifungal agents, as determined by the CLSI and Vitek 2 yeast susceptibility test methods

Antifungal agentTest methodcNo. of occurrences at an MIC (μg/ml) of:Essential agreement (%)aTentative MIC breakpoint (µg/ml)bResistance (%)bCategorical agreement (%)b
≤0.030.060.1250.250.512481632≥64
FluconazoleCLSI4676102896.7≥3262.393.4
Vitek 2113171122662.3
VoriconazoleCLSI887713125188.5NAdNANA
Vitek 230265NA
Amphotericin BCLSI22930100≥20100
Vitek 25650
CaspofunginCLSI1951100≥20100
Vitek 2610
MicafunginCLSI1114324100≥40100
Vitek 25920
  • a Essential agreement (±2 log2 dilutions) between the CLSI and Vitek 2 yeast susceptibility tests.

  • b Results of resistance and categorical agreement were analyzed using the tentative CLSI MIC breakpoints for C. auris published by the Centers for Disease Control (CDC) (https://www.cdc.gov/fungal/candida-auris/recommendations.html).

  • c CLSI test method refers to the CLSI M27-3A broth microdilution method after a 24-h incubation.

  • d NA, not available.